Are you a Health Professional? Jump over to the doctors only platform. Click Here

Why Cisplatin Kills Breast Cancer Cells When Other Drugs Fail

young woman with bald head jogging after chemotherapy
Print Friendly, PDF & Email

The cancerous cells of some individuals with breast cancer lack expression of two cell surface proteins, the estrogen and progesterone receptors, and do not express increased amounts of HER2.

Individuals with such breast cancer (known as triple-negative breast cancer) do not respond to treatment with commonly used chemotherapeutic drugs and their prognosis is relatively poor. But now, a new study from researchers at Massachusetts General Hospital Cancer Center, Boston, has indicated that triple-negative breast cancer cell lines are sensitive to exposure to the chemotherapeutic cisplatin.In the study, which appears online in advance of publication in the May print issue of the Journal of Clinical Investigation, Leif Ellisen and colleagues show that triple-negative breast cancer specimens express increased amounts of two proteins, delta-Np63 and TAp73. Delta-Np63 was shown to bind TAp73 and prevent it from killing the cancerous cells. Importantly, the chemotherapeutic drug cisplatin, but not other commonly used chemotherapeutic drugs, was found to release TAp73 from delta-Np63, causing the cells to be killed. This study indicates that individuals with triple-negative breast cancer might benefit from early treatment with cisplatin if their cancerous cells express increased amounts of delta-Np63 and TAp73.(Source: Journal of Clinical Investigation : Harvard Medical School : May 2007.)


Print Friendly, PDF & Email

Dates

Posted On: 26 April, 2007
Modified On: 16 January, 2014

Tags



Created by: myVMC